[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital of North Norway\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":510},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,48,77,107,140,167,195,223,250,276,298,326,355,381,404,439,461,484],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100523038","phase-1-ketamine-for-combined-depression-and-alcohol-use-disorder-100523038",false,"NCT06090422","Ketamine for Combined Depression and Alcohol Use Disorder","Ketamine for Combined Depression and Alcohol Use Disorder: A Blinded Randomized Active Placebo-controlled Trial (the KeDA Trial)","KeDA","Please contact the project team for a full and detailed list of inclusion\u002Fexclusion criteria\n\nInclusion Criteria:\n\n* Currently abstinent from alcohol\n* At least moderate depression without psychotic features\n* Minimum Montgomery-Åsberg Depression Rating Scale (MADRS) of 20\n* Alcohol dependence\n* Admitted for inpatient addiction therapy at University Hospital of North Norway\n\nExclusion Criteria:\n\n* Intoxicated or in significant withdrawal from alcohol or drug use\n* Not able to give adequate informed consent\n* Current or past history of schizophrenia, schizophreniform disorder, paranoid delusional disorder, schizoaffective disorder\n* Current or historical diagnosis of schizophrenia in a first degree relative\n* Cardiovascular conditions: recent stroke (\\\u003C 1 year from informed consent), recent myocardial infarction (\\\u003C 1 year from informed consent), uncontrolled hypertension (\\>150\u002F100 mm Hg) or recent arrhythmia (\\\u003C 1 year from informed consent; clinically significant arrhythmia requiring treatment at hospital)\n* Liver (Child-Pughs Class C) or kidney (Creatinin clearance \\\u003C 30 mL\u002Fmin) failure\n* Heart failure (the New York Heart Association Functional Classification (NYHA) class III or IV)\n* Chronic respiratory failure (requiring long-term oxygen therapy (LTOT) and\u002For Global Initiative for Chronic Obstructive Lung Disease system (GOLD) stage 3 or higher)\n* Previous anaphylactic reaction to ketamine or midazolam\n* Illegal use of ketamine the last 6 months\n* Pregnancy or breastfeeding\n* Current or suspected increased intracranial pressure","ALL","18 Years","65 Years",{"count":21,"type":22},34,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.",[29,30],"Depression","Alcohol Use Disorder",[29,32,33,34],"Alcohol use disorder","Ketamine","Addiction","RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-23","ACTUAL",{"date":41,"type":39},"2025-01-20",{"date":43,"type":22},"2027-07-01",{"name":45,"class":46},"University Hospital of North Norway","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100618487","phase-1-alzheimers-disease-and-faecal-microbiota-transplantation--a-pilot-study-100618487","NCT07332260","Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study","Alzheimer's Disease and Faecal Microbiota Transplantation","AD-FMT","Inclusion Criteria:\n\n* Alzheimer's dementia mild to moderate stage\n* Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024)\n* Capable of giving informed consent\n\nExclusion Criteria:\n\n* Contraindications for colonoscopy examination\n* Contraindications for Magnetic Resonance Imaging (MRI)\n* Life expectancy \\\u003C 1 year\n* Clinical frailty scale 7 or more\n* History of seizure disorder\n* History of brain tumour or intracranial bleed\n* Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder\n* Alcohol or substance abuse\n* Decompensated heart disease\n* Malignancy\n* Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin)\n* Pregnant or planning pregnancy\n* Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy\n* Status after colectomy or hemicolectomy\n* Inflammatory bowel disease\n* Immunocompromised individual\n* Receiving biological\u002Fantibody treatment",{"count":57,"type":22},10,[25],"The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.",[61,62],"Alzheimer s Disease","Faecal Microbiota Transplantation (FMT)",[64,65,66,67,68],"Alzheimer's disease","Dementia","Gut microbiota","faecal microbiota transplantation","FMT","2026-04-17",{"date":71,"type":39},"2026-04-22",{"date":73,"type":22},"2026-05",{"date":75,"type":22},"2027-01",{"name":45,"class":46},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100633738","decentralized-imaging-by-remote-computer-tomography-for-cerebral-infarct-thrombolysis-100633738","NCT07530588","Decentralized Imaging by REmote Computer Tomography for Cerebral Infarct Thrombolysis","Remote Controlled CT Scanning for Decentralized Diagnostics and Treatment Versus Standard Care in Acute Stroke","DIRECT-CT","Inclusion Criteria:\n\n\\- Patients in the catchments areas of the intervention and control group presenting with a clinical suspected diagnosis of stroke within symptom onset within the last 24 hours\n\nExclusion Criteria:\n\n\\- Patients presenting with a clinical suspected diagnosis of stroke more than 24 hours after symptom onset",{"count":86,"type":22},52,[88],"NA","The DIRECT-CT trial is designed to test the hypothesis that remote controlled CT scanning combined with real time audio-and video conference (AVC) guided assessment from an experienced hospital stroke team (tele-stroke) at decentralized medical centers (DMC) reduces time to intravenous thrombolytic treatment compared to the standard pathway.",[91],"Stroke",[91,93,94,95,96,97],"Rural","Prehospital diagnostics and treatment","Remote controlled computer tomography","Intravenous thrombolysis","District medical center","2026-04-10",{"date":100,"type":39},"2026-04-15",{"date":102,"type":39},"2025-07-17",{"date":104,"type":22},"2028-12-31",{"name":45,"class":46},2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":106},"100619382","population-based-atrial-fibrillation-screening-in-individuals-with-nt-probnp-above-median-in-the-troms-study-100619382","NCT07343895","Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study","Atrial Fibrillation and Long Term ECG Monitoring of Heart Rhythm in the Tromsø Study","PAFS-Tromsø","Inclusion Criteria:\n\n* Age ≥40 years\n* NT-proBNP\\> median level\n* Informed consent for participation\n\nExclusion Criteria:\n\n* History of AF (self-reported)\n* Use of anticoagulation therapy\n* Pacemaker\u002FCRT device\n* No available smart phone",true,"40 Years",{"count":118,"type":22},4000,[88],"The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and measurements of height, weight, blood pressure, and ECG.\n\nA total of 4,000 individuals with NT-proBNP levels above the median, without previously known atrial fibrillation (AF) or ongoing anticoagulation therapy, will be randomized to either long-term heart rhythm monitoring (7 days) or a control group without long-term ECG monitoring (2,000 in each group). Individuals with AF in the intervention group will be offered anticoagulation therapy in accordance with current guidelines.\n\nThe intervention group and the control group will be compared with regards to incident stroke and death within a 6-year follow-up period. Information on endpoints and anticoagulation use will be obtained through linkage to national registries.",[122,91,123,124,125],"Atrial Fibrillation (AF)","NT-pro-BNP","Cognitive Function and Well-Being","Heart Failure",[127,128,91,129,130,131,125],"ECG247","Atrial Fibrillation","NT-Pro-BNP","Cognitive decline","Life Quality","2026-01-06",{"date":134,"type":39},"2026-01-15",{"date":136,"type":39},"2025-10-24",{"date":138,"type":22},"2035-03-01",{"name":45,"class":46},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":147,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":47},"100613403","virtual-biopsy-of-prostate-cancer-using-psma-pet-and-ai-100613403","NCT07266129","Virtual Biopsy of Prostate Cancer Using PSMA PET and AI","Prostate Cancer Malignancy Grading Using Prostate Specific Membrane Antigen (PSMA) PET and Machine Learning","Inclusion Criteria:\n\n* For patients who have undergone biopsies prior to PET:\n* Patients referred to clinical PET examination\n* For patients who have not had biopsies prior to PET:\n* Patients referred to urologist for suspected prostate cancer based on clinical symptoms or elevated PSA-levels\n\nExclusion Criteria:\n\n* Prostatektomy\n* Body weight under 100 kg\n* MRI incompatible implants or other incompatibilities","MALE",{"count":149,"type":22},220,"OBSERVATIONAL","Prostate cancer is the most common type of cancer in Norwegian men, but many tumors are slow-growing and do not require treatment. Today, MRI is good at detecting suspicious lesions, yet it cannot reliably distinguish aggressive tumors from low-grade ones. As a result, many men undergo repeated invasive biopsies. New PET tracers targeting PSMA improve tumor localization and may correlate with cancer aggressiveness, offering potential for better assessment.\n\nThis project aims to develop a method to predict Gleason Score non-invasively by applying machine learning to PET and MRI data. The work involves early static and dynamic PSMA PET imaging, tracer kinetic modelling, deep learning, and validation of PET-based measurements of PSMA internalization using ex-vivo cellular methods.\n\nIf successful, the project could reduce the number of biopsies, improve diagnostic accuracy, offer full 3D assessment of the prostate, shorten clinical workflows, and help identify patients who would benefit most from PSMA-based radioligand therapy.",[153],"Prostate Cancer (Diagnosis)",[155,156,157,158],"Prostate Cancer","Artificial Intelligence","Positron Emission Tomography","Prostate Specific Membrane Antigen","2025-11-24",{"date":161,"type":39},"2025-12-05",{"date":163,"type":39},"2024-06-03",{"date":165,"type":22},"2027-12",{"name":45,"class":46},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":194},"100551075","patient-centered-dosage-of-levothyroxine-100551075","NCT06455371","Patient-centered Dosage of Levothyroxine","Patient-centered Decision Support Tool for Levothyroxine Dosage","Inclusion Criteria:\n\n* Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals\n\nExclusion Criteria:\n\n* Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy",{"count":175,"type":22},240,[88],"Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.",[179,180,181],"Hypothyroidism","Thyroid Cancer","Thyroid",[183,184,185,186],"Decision support tool","Patient-centered dosage","thyroidectomy","levothyroxine","2025-09-03",{"date":189,"type":39},"2025-09-10",{"date":191,"type":39},"2024-12-20",{"date":165,"type":22},{"name":45,"class":46},3,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":211,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":220,"leadSponsor":222,"locationsCount":47},"100604417","the-effect-of-a-6-month-dietitian-tailored-nutrition-intervention-to-patients-with-critical-illness-detail-100604417","NCT07149246","The Effect of a 6-month Dietitian-tailored Nutrition Intervention to Patients With Critical Illness (DETAIL)","The Effect of a 6-month DiEtitian-TAILored Nutrition Intervention Compared to Usual Care in Patients With Critical Illness. A Single Center Prospective Intervention Study","DETAIL","Inclusion Criteria: Patients in intensive care who gives an informed consent and meet all of the following will be eligible:\n\n1. Admitted to the intensive care unit for \\>48 hours.\n2. At least 18 years of age\n3. Have one or more organ system failure (respiratory,cardiovascular or renal) related to their acute illness defined as:\n\n   a. PaO2\u002FFiO2≤300 mm Hg) b. Currently on one or more continuous inotrope\u002Fvasopressor infusion which were started at least 4 hours ago at a minimum dose of: i. Norepinephrine≥0.1 mcg\u002Fkg\u002Fmin ii. Epinephrine≥0.1 mcg\u002Fkg\u002Fmin iii. Any dose of vasopressin iv. Milrinone\\>0.1 mcg\u002Fkg\u002Fmin) c. Renal dysfunction defined as: i. Serum creatinine 2.0-2.9 times baseline or ii. Urine output 0.5 mL\u002Fkg\u002Fhour for ≥12 hours or iii. Currently receiving renal replacement therapy) d. Currently has an intracranial pressure monitor or ventricular drain in situ\n4. Permanent living address in Norway\n\nExclusion Criteria: Patients will be excluded if:\n\n1. Death is imminent in the next 96 hours or there is a current treatment limitation in place or the patient is unlikely to survive to 180 days due to underlying\u002Fchronic illness\n2. Dialysis dependent chronic renal failure\n3. Suspected or known pregnancy\n4. Wheelchair user\n5. Cognitive impairment in which intervention is considered not appropriate\n6. Eating disorders -",{"count":204,"type":22},300,[88],"This research project aims to study the effect of optimal and individualised nutrition to patients with critical illness during the intensive care unit (ICU) and hospital admission, and until six months after admission. The investigators want to describe and compare the usual care with a dietitian-tailored nutrition care. The hypothesis is that dietitian-tailored nutrition care will result in a higher mean energy intake compared to usual care.",[208,209,210],"ICU Patients","Nutrition Intake","Critical Illness",[212,213,214,215,216],"Nutrition","Energy intake","Protein intake","ICU","Dietitian","2025-09-01",{"date":187,"type":39},{"date":217,"type":39},{"date":221,"type":22},"2028-03-31",{"name":45,"class":46},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":249,"locationsCount":47},"100600085","myocardial-infarction-safe-emergency-medicine-accompanying-study-providing-reperfusion-therapy-within-the-recommended-time-limits-100600085","NCT07092904","Myocardial Infarction Safe Emergency Medicine Accompanying Study: Providing Reperfusion Therapy Within the Recommended Time Limits","iTide 2 - STEMI Follow-up Study","Inclusion Criteria:\n\n* Patient with the diagnosis of acute ST elevation myocardial infarction located within the uptake area of the Northern Norway Regional Health Authority\n\nExclusion Criteria:\n\n* Patient declines use of data",{"count":231,"type":22},200,"The project is a prospective observational study with the aim of system improvement. It represents accompanying research in connection with the implementation of Safe Emergency Medicine , - an initiative under the auspices of the board of The North Norway Regional Health Authority and The Municipal Health Consortium that aims to provide faster and better treatment to patients with common, serious and time-critical conditions.\n\nThe focus of the study is the decision-making process and implementation of treatment algorithms for all patients with acute ST-elevation myocardial infarction (STEMI) in the regional health trust's admission area. The data sources are 1) structured telephone interviews with providers and decision-makers and 2) electronic medical records (AMIS, DIPS, prehospital medical records from emergency departments, ambulance medical records). The analyses will form the basis for recommendations for improvements in procedures, training and organization.",[234],"Infarction",[236,237,238,239,240,241],"Acute myocardial infarction","Pharmacoinvasive","Reperfusion therapy","Emergency medicine","Prehospital thrombolysis","primary PCI","NOT_YET_RECRUITING","2025-07-21",{"date":245,"type":39},"2025-07-30",{"date":217,"type":22},{"date":248,"type":22},"2026-04-30",{"name":45,"class":46},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":47},"100508705","improving-stroke-care-in-north-norway-through-artificial-intelligence-100508705","NCT05903898","Improving Stroke Care in North-Norway Through Artificial Intelligence","Inclusion Criteria:\n\n* Patients with acute stroke symptoms admitted to a participating hospital within 24 hours of symptom onset\n\nExclusion Criteria:\n\n* Patients not available for follow-up assessments (e.g. non-resident)",{"count":257,"type":22},1000,[88],"Prospective observational multi-center intervention study. The study aims to evaluate whether an artificial intelligence (AI) support tool for radiological image processing (StrokeSens, Circle NVI) can accelerate decision making and increase detection rate in patients with an acute ischemic stroke caused by intracranial large vessel occlusion (LVO) or medium vessel occlusion (MeVO) in Northern Norway. Relevant outcomes will be compared between centres with and without available software during the study period.",[261],"Ischemic Stroke",[263,264,265,266,267],"Large vessel occlusion","Artificial intelligence","Thrombectomy","Interhospital transfer","Medium sized vessel occlusion","2025-07-18",{"date":270,"type":39},"2025-07-23",{"date":272,"type":39},"2023-06-01",{"date":274,"type":22},"2030-12-31",{"name":45,"class":46},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":283,"enrollmentInfo":284,"targetDuration":286,"studyType":150,"phases":4,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":47},"100492628","investigations-into-sepsis-associated-acute-kidney-injury-100492628","NCT05694624","Investigations Into Sepsis-associated Acute Kidney Injury","Investigations Into the Mechanisms for Bioenergetic Failure in Sepsis-associated Acute Kidney Injury","Inclusion Criteria sepsis group:\n\n* Sepsis diagnosed or suspected\n* Normal premorbid serum creatinine measured or anticipated (if data are not available)\n* Normovolemia as indicated by a pulse pressure variation less than 12%\n\nComparator group\n\n* Previously healthy individuals scheduled for laparoscopic colon cancer resection\n* Normal creatinine levels within 3 months before admittance to hospital.\n\n  * Patients admitted to the intensive care unit with sepsis diagnosed or suspected\n  * Previously healthy patients listed for elective colon cancer surgery\n\nExclusion Criteria:\n\n\\-","100 Years",{"count":285,"type":22},20,"2 Days","In this study the investigators would like to study systemic and regional disturbances in patients with sepsis-associated acute kidney injury and in healthy controls undergoing laparoscopic abdominal surgery. Specifically study metabolic, hemodynamic and oxygen transport variables.",[289],"Acute Kidney Injury","2025-03-18",{"date":292,"type":39},"2025-03-21",{"date":294,"type":39},"2023-08-14",{"date":296,"type":22},"2026-12-31",{"name":45,"class":46},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":283,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":314,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":47},"100578105","artificial-intelligence-enabled-decision-support-for-selection-of-patients-for-lumbar-spine-surgery-100578105","NCT06806969","Artificial Intelligence Enabled Decision Support for Selection of Patients for Lumbar Spine Surgery","Artificial Intelligence (AI) Enabled Decision Support Tool for Selection of Patients for Lumbar Spine Surgery: a Feasibility Study","Inclusion Criteria:\n\n* Patients with MRI-confirmed LDH or LSS referred to University hospital of North Norway Tromsø for assessment of indication for surgery\n* Specialists and physicians in training (for two years or more) in neurosurgery or orthopedic surgery who evaluate such patients at the neurosurgical outpatient clinic at University hospital of North Norway Tromsø\n\nExclusion Criteria:\n\n* Patients unable to consent because of\n\n  * Age \\\u003C 18 years\n  * Serious drug abuse of severe psychiatric disorders\n  * Language barriers (patients who cannot speak or read Norwegian)\n* Patients with a baseline ODI ≤14 (LDH) or ≤22 (LSS)\n* Patients undergoing non-elective\u002Femergency operations\n* Patients with degenerative conditions other that LDH and LSS, fractures, primary infections, or malignant conditions of the spine\n* Physicians in training with less than two years' experience with spine surgery",{"count":306,"type":22},26,[88],"Background One third of patients operated for lumbar disc herniation (LDH) or spinal stenosis (LSS) do not achieve substantial improvement. Studies indicate that well informed shared decision making (SDM) can improve the selection to surgery, and thus the outcomes. Numerous algorithms for outcome prediction have therefore been developed, and some use artificial intelligence (AI). Most are trained on small datasets, few are accurate, all are stand-alone or web-based applications not integrated in the electronic health record (EHR), and none are implemented in routine clinical practice.\n\nThe Norwegian registry for spine surgery (NORspine) comprises a cohort of more than 69,000 cases. The investigators have used AI to analyze the dataset and predict the outcome, and developed a decision support tool (DST) which is seamlessly integrated in the EHR DIPS Arena®.\n\nThe investigators intend to use the tool to inform the SDM between surgeons and patients about the indication for surgery (yes or no), to increase the proportion with a successful outcome. The aim of the study is to assess the safety and feasibility of the DST for use in a subsequent pilot study.\n\nThe device The DST (the device) is an integrate compound of software-solutions. Baseline data are registered by patients and surgeons on questionnaires integrated in DIPS Arena®, and transferred to NORspine. The data are also transferred (de-identified) to the AI-enabled prediction algorithm which operates in a cloud-based model hosting service. The algorithm has been trained and validated on a dataset from NORspine. The area under the curve for prediction of the main outcome (Oswestry disability index after12 months) in receiver operating characteristic analysis is very high (0.85) for LDH and moderate (0.72) for LSS. The model host also calculates outcomes (proportions with substantial, slight, or no improvement, and worsening) for the 50 cases with baseline variables most similar to the present case (\"patients-like-me\"). Finally, the individual prediction and the outcomes for the \"patients-like-me\" are transferred back and displayed in the regular user interface of DIPS Arena® for use in the SDM.\n\nClinical investigations For this feasibility study, the investigators will use convergent qualitative and quantitative mixed methods. The comparator is decision making in routine clinical practice, without use of the DST. The study will include 20 patients with magnetic resonance imaging confirmed LDH or LSS referred for evaluation of the indication for surgery, and six surgeons who do the evaluations. The study will iteratively redesign the user interface of the DST until it is considered safe and feasible for use in a following pilot study.",[310,311,312,313],"Intervertebral Disc Displacement","Spinal Stenosis Lumbar","Lumbar Disc Herniation","Lumbar Spine Degeneration",[315,316,317],"artificial intelligence","decision support","surgery selection","2025-01-30",{"date":320,"type":39},"2025-02-04",{"date":322,"type":22},"2025-02-01",{"date":324,"type":22},"2027-06-30",{"name":45,"class":46},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":333,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":47},"100574307","necrotizing-enterocolitis-and-bowel-perforation-in-very-preterm-infants---long-term-follow-up-100574307","NCT06757582","Necrotizing Enterocolitis and Bowel Perforation in Very Preterm Infants - Long-term Follow up","NOR-NEC","Inclusion Criteria:\n\n* Case: All Norwegian very preterm infants (gestational age (GA) \\\u003C 32 weeks) born during the 6-year period 2008-2013, diagnosed with surgical NEC or bowel perforation and surviving up to one year of age will be invited to participate as cases.\n* Controls: For each case we will invite two controls matched for important clinical characteristics (e.g. sex, GA, clinical illness score, intracranial pathology, need for oxygen at discharge etc.).\n\nExclusion Criteria:\n\n* not signing informed consent scheme","6 Years","15 Years",{"count":336,"type":22},150,"Necrotizing enterocolitis (NEC) is a gastrointestinal syndrome characterized by transmural inflammation and necrosis of the large and\u002For small bowel and subsequent intramural gas-forming organisms into the intestinal wall. Some preterm infants also develop spontaneous intestinal perforations (SIP) without the classical bowel inflammation\u002Fnecrosis seen in NEC. NEC and SIP can be challenging to differentiate. Severe cases of both conditions require surgery and often bowel resection, but mortality due to SIP seems lower.\n\nStudies looking at \"long-term prognosis\" of infants with NEC and bowel perforation have mainly assessed outcome until 2-7 years of age. The primary school years is a vulnerable period for ex-preterm children. Disruption in learning and social integration is of great importance for their quality of life (QoL), but little data exist in this age group. Moreover, nutritional deficits (e.g. cobalamin- or iron-deficiency may impact cognitive development, but this has not been investigated in this \"high-risk\" population in school age. Authors of a recent systematic review on gastrointestinal sequel after NEC-surgery thus called for \"more high-quality studies assessing long-term follow-up\".\n\nIn this project we will study the long-term impact of surgery for NEC and bowel perforation in preterm infants, both with a quality of life (QoL) perspective and with a focus on development, growth, nutrition and persistent gastrointestinal problems.",[339,340,341],"Necrotizing Enterocolitis","Intestinal Perforation","Premature Infant Disease",[343,344,345,346,347],"necrotizing enterocolitis","bowel perforation","preterm infant","long-term follow-up","quality of life","2025-01-02",{"date":350,"type":39},"2025-01-03",{"date":322,"type":22},{"date":353,"type":22},"2027-08-01",{"name":45,"class":46},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":364,"studyType":150,"phases":4,"briefSummary":365,"conditions":366,"keywords":368,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":380,"locationsCount":47},"100547368","long-term-reoperations-after-lumbar-spinal-stenosis-surgery-100547368","NCT06407063","Long-term Reoperations After Lumbar Spinal Stenosis Surgery","Long-term Frequency of Reoperations After Micro-decompression Alone Versus Decompression and Instrumented Fusion in Patients With Lumbar Spinal Stenosis and Degenerative Spondylolisthesis","Inclusion Criteria:\n\n* operated between September 2007 and December 2015 labeled in the registry with both 'Spinal stenosis' and 'Degenerative spondylolisthesis'\n* operated on with decompression with or without an additional fusion\n\nExclusion Criteria:\n\n* operated with an anterior approach\n* had a former operation at index Level\n* was labeled with a degenerative scoliosis\n* was operated in more than 2 Levels\n* was operated with non-instrumented fusion\n* operated with a standard laminectomy with removing of the posterior midline structures or operated without magnifying devices was excluded from the micro-decompression group",{"count":363,"type":22},794,"8 Years","Severe and persisting pain and disability due to a degenerative narrowing of the spinal canal, lumbar spinal stenosis, can be operated with a simple surgical decompression. Sometimes, there is also a slippage of vertebra, degenerative spondylolisthesis. In such cases, instrumental stabilization (e.g. screws and rods) has been recommended. Even though additional fusion is more complex and riskier, and evidence in high-quality Scandinavian studies shows that it is unnecessary, decompression plus fusion is still the treatment of choice in the USA and most European countries. This reluctance to change clinical practice is mainly due to concerns about long-term results, especially higher reoperation rates among patients operated with decompression only. This register-based non-inferiority study aims to assess long-term reoperations among those treated with and without additional fusion surgery.",[367],"Degenerative Lumbar Spondylolisthesis",[369,370,371,372,373],"Degenerative Spondylolisthesis","Treatment","Decompression alone","Instrumented fusion","Reoperations","2024-12-11",{"date":376,"type":39},"2024-12-17",{"date":378,"type":39},"2007-09-19",{"date":248,"type":22},{"name":45,"class":46},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":388,"maxAge":19,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":47},"100557174","the-cerebral-and-cognitive-changes-after-intermittent-theta-burst-stimulation-itbs-treatment-for-depression-100557174","NCT06534684","The Cerebral and Cognitive Changes After Intermittent Theta Burst Stimulation (iTBS) Treatment for Depression","The Cerebral and Cognitive Changes After Intermittent Theta Burst Stimulation (iTBS) Treatment for Depression A Randomised Double-blind Sham-controlled Trial","Inclusion criteria:\n\n* Patients must meet the diagnostic criteria of at least a moderate depression\n* The duration of the current depressive episode must have lasted more than 2 weeks but less than 2 years\n* Drug therapy must have been stable for the last three weeks prior to the first treatment day with iTBS\n* Patients must volunteer to provide informed consent, be able to follow the treatment schedule and have a satisfactory safety screening for iTBS and MRI\n\nExclusion criteria:\n\n* The current depressive episode is in the mild range\n* The current episode fulfills the criteria for a major depressive episode requiring inpatient treatment and\u002For electroconvulsive therapy,\n* The current depressive episode is clearly triggered by grief or a recent major stressful life event\n* Bipolar disorder\n* Borderline personality disorder\n* Psychotic symptoms\n* Alcohol or substance abuse\u002Faddiction in the last 6 months\n* Current eating disorders\n* Obsessive- compulsive disorders\n* Post-traumatic stress disorder\n* A life-time medical history of seizure\n* Neurological or neurosurgical pathologies\n* Cardiac or systemic disease\n* Metallic prosthetic material or foreign objects (pacemakers, prosthetic eye equipment, etc.)\n* Autism\n* Pregnancy\n* Currently using of antipsychotic medication or benzodiazepines - or any medication that interferes with motor threshold excitability","22 Years",{"count":390,"type":22},50,[88],"The present project aims to assess the neurocognitive impact of a two-week once-a-day regimen of intermittent theta burst stimulation (iTBS) compared to sham iTBS, when targeting the left dorsolateral prefrontal cortex (LDLPFC) in clinically depressed outpatients. The study investigates the relationships between changes in cerebral measures and cognitive performance on an N-back task in relation to the antidepressive effect following iTBS.",[394,395],"Depression, Unipolar","Depression Moderate","2024-08-01",{"date":398,"type":39},"2024-08-02",{"date":400,"type":39},"2024-02-12",{"date":402,"type":22},"2029-02-12",{"name":45,"class":46},{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":426,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":47},"100550785","phase-2-fecal-microbiota-transplantation-in-axial-spondyloarthritis-100550785","NCT06451588","Fecal Microbiota Transplantation in Axial Spondyloarthritis","Donor Versus Autologous Fecal Microbiota Transplantation for Axial Spondyloarthritis: a Double Blind, Placebo-Controlled, Randomized Trial","MicroSpA","Inclusion Criteria:\n\n* Axial Spondyloarthritis according to the ASAS classification criteria\n* Active disease defined as ASDAS ≥2.1 with elevated CRP ≥4 OR active inflammation on MRI within the last 3 months\n* Onset of axial SpA within last 10 years\n* Unsatisfactory relief of NSAIDs\n* On stable immunomodulatory treatment (TNFi, IL17i or JAKi) the last 3 months\n\nExclusion Criteria:\n\n* Planned dose adjustment or change in immunomodulatory treatment the next 90 days\n* Disease or disorder with life expectancy of ≤5 years\n* Severe immune deficiency (acquired, congenital og du to medication)\n* Previous treatment with FMT\n* Regular use of opioids with the exception of codeine and tramadol\n* Any specific diagnosis that could explain or contribute to the patients back pain (e.g. tumor, fracture, infection or degenerative disease)\n* Inflammatory spinal disease other than axSpA\n* Severe psychiatric disorder, alcohol- or drug abuse\n* Active inflammatory bowel disease\n* Microscopic colitis, diverticulitis or ileus\n* Active psoriasis\n* Fibromyalgia\n* Abdominal surgery excluding appendectomy, cholecystectomy, hysterectomy, caesarian section, sapling-ooforectomy and hernia surgery\n* Malignant disease excluding basalioma and melanoma stage 1\n* Conditions with expected necessary treatment with antibiotics during the study period, e.g. periodontitis end ischemic digital ulcers\n* Treatment with antibiotics 12 weeks prior to study entry\n* Pregnancy, lactation or planned pregnancy within the next 3 months\n* Contraindications for rectal catheter insertion\n* Planned rehabilitation program the next 90 days\n* Limited ability to comply with protocol requirements, including biobank participation",{"count":413,"type":22},99,[26],"Although biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints.\n\nIt has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gut compared to healthy controls, and that this correlates to disease activity and respons to therapy.\n\nThe goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of biologic therapy.\n\nThe main questions it aims to answer are:\n\n* Can FMT reduce disease activity in axial SpA?\n* Can FMT alleviate pain and reduce fatigue in axial SpA?\n* Is the composition of microorganisms restored to normal in patients with SpA after a treatment with FMT?\n\nParticipants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline. The primary endpoint will be evaluated after 90 days, but efficacy and safety will be monitored from baseline until 365 days.",[417,418,419,420,421,422,423,424,425],"Axial Spondyloarthritis","Ankylosing Spondylitis","Dysbiosis","Spondyloarthritis","Spondylitis","Arthritis","Musculoskeletal Diseases","Spinal Disease","Joint Diseases",[417,427,428,429,68,430],"Microbiome","Fecal Microbiota Transplantation","Microbiota","RCT","2024-06-04",{"date":433,"type":39},"2024-06-11",{"date":435,"type":39},"2024-06-01",{"date":437,"type":22},"2026-03",{"name":45,"class":46},{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":242,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":460,"locationsCount":194},"100523493","gastropexy-as-a-treatment-option-for-paraesophageal-hernia-100523493","NCT06096402","Gastropexy as a Treatment Option for Paraesophageal Hernia","Selective Anterior Gastropexy as a Surgical Treatment Option for Paraesophageal Hernia","Inclusion Criteria:\n\n\\- Both emergent and elective repair of the paraoesophageal hernia\n\nExclusion Criteria:\n\n\\-",{"count":149,"type":22},"The present proposal aims to asses which is the optimal treatment strategy in a clinical study in patients with paraoesophageal hernia (PEH), a condition often found in elderly, fragile patients The investigator want to study the optimal approach to a paraoesophageal hernia (PEH) repair. The incidence of PEH increases with age and the older patient typically has additional co-morbidities, reduced physiological fitness, and frailty which makes surgery challenging regarding increased morbidity and mortality. Thus, the decision to offer surgery can be challenging in this cohort of patients. The need of an anti-reflux procedure as part of the repair is one of the main subjects for discussion worldwide. To date no consensus exists and many surgical centres do a routine anti-reflux procedure as part of their standard operation for PEH. But is this procedure redundant? Can the patients be managed with a less complicated procedure; an anterior gastropexy with comparable outcome?",[449],"Paraesophageal Hernia",[451,452,453],"paraesophageal hernia","gastropexy","fundoplication","2023-10-20",{"date":456,"type":39},"2023-10-23",{"date":435,"type":22},{"date":459,"type":22},"2027-12-31",{"name":45,"class":46},{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":483,"locationsCount":47},"100485860","drug-free-without-toothache-a-study-of-free-dental-treatment-as-a-part-of-substance-abuse-treatment-100485860","NCT05606562","Drug-free Without Toothache. A Study of Free Dental Treatment as a Part of Substance Abuse Treatment","Drug-free Without Toothache. A Non-randomized Intervention Study of Free Dental Treatment as a Part of Substance Abuse Treatment.","RUST","Inclusion Criteria:\n\nPeople who are hospitalized for drug abuse at Russeksjon UNN Narvik.\n\nExclusion Criteria:\n\nNon",{"count":390,"type":22},[88],"Objectives: The main objective of the study is to investigate\n\n1. How many patients will attend and complete dental care if they are offered it for free during the stay at \"The department of substance abuse treatment, University Hospital North Norway (UNN) in Narvik\".\n2. Explore whether a parallel dental treatment in addition to the other treatment at the department has a beneficial effect on the abuse treatment, or whether it can be disruptive to offer dental treatment in combination with admission for drug rehabilitation?",[473,474],"Substance Abuse","Dental Caries",[476],"Non Randomized Interventional study","2022-10-31",{"date":479,"type":39},"2022-11-04",{"date":481,"type":39},"2022-04-06",{"date":296,"type":22},{"name":45,"class":46},{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":283,"enrollmentInfo":492,"targetDuration":334,"studyType":150,"phases":4,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":47},"100385035","prediction-of-outcome-by-echocardiography-in-left-bundle-branch-block-100385035","NCT04293471","Prediction of Outcome by Echocardiography in Left Bundle Branch Block","Prediction of Heart-failure and Mortality by Echocardiographic Parameters and Machine Learning in Individuals With Left Bundle Branch Block","EchoLBBB","Inclusion Criteria:\n\n* QRS complex \\>130 ms and R-wave duration in\n* V6 \\>70 ms\n* ventricular pacing\\>50%\n* Previously implanted cardiac resynchronisation therapy (CRT)\n\nExclusion Criteria:\n\n* Typical right bundle branch block.\n* No ability to give informed consent,\n* non-cardiovascular co-mobidities with reduced life-expectancy \\\u003C 1 year\n* patients with complex congenital heart disease.",{"count":493,"type":22},2000,"Patients with left bundle branch block have an increased risk for the development of heart-failure and death. However, risk factors for unfavorable outcomes are still poorly defined. This study aims to identify echocardiographic parameters and ECG characteristics by machine learning in order to develop individual risk assessment",[496],"Left Bundle-Branch Block",[498,499,500,501],"Left bundle branch block","strain-imaging","myocardial work assessment","machine learning","2022-05-18",{"date":504,"type":39},"2022-05-24",{"date":506,"type":39},"2021-04-15",{"date":508,"type":22},"2036-12-31",{"name":45,"class":46},""]